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Abstract
Background: Targeted sequencing using oncopanels requires comprehensive
assessments of accuracy and detection sensitivity to ensure analytical validity. By
employing reference materials characterized by the U.S. Food and Drug
Administration-led SEquence Quality Control project phase2 (SEQC2) effort, we
perform a cross-platform multi-lab evaluation of eight Pan-Cancer panels to assess
best practices for oncopanel sequencing.
Results: All panels demonstrate high sensitivity across targeted high-confidence
coding regions and variant types for the variants previously verified to have variant
allele frequency (VAF) in the 5–20% range. Sensitivity is reduced by utilizing VAF
thresholds due to inherent variability in VAF measurements. Enforcing a VAF
threshold for reporting has a positive impact on reducing false positive calls.
Importantly, the false positive rate is found to be significantly higher outside the
high-confidence coding regions, resulting in lower reproducibility. Thus, region
restriction and VAF thresholds lead to low relative technical variability in estimating
promising biomarkers and tumor mutational burden.
Conclusion: This comprehensive study provides actionable guidelines for oncopanel
sequencing and clear evidence that supports a simplified approach to assess the
analytical performance of oncopanels. It will facilitate the rapid implementation,
validation, and quality control of oncopanels in clinical use.
Keywords: Oncopanel sequencing, Target enrichment, Molecular diagnostics,
Reproducibility, Analytical performance, Precision medicine
Background
Despite ongoing advances in sequencing technologies to date, the promise of their use
for precision medicine has not yet borne out entirely for the majority of cancer pa-
tients. Although cancer is a genomic disease, most malignant tumors are currently clas-
sified and often treated based on the tissue of origin and the TNM (tumor, node, and
metastases) staging system for solid tumors rather than presence or absence of relevant
mutations in key oncogenic pathways. Presently, only a small number of specific muta-
tions in genes such as EGFR, ALK [1], and BRAF [2] are routinely tested to inform clin-
ical decisions. To move precision medicine from theoretical discussions to the bedside
of individual patients, it requires accurate and reproducible testing of a broad spectrum
of clinically relevant mutations combined with appropriate therapies. Hence, improved
mutation testing is greatly needed to confidently classify individual tumors, reliably pro-
vide personalized therapeutic choices, and inform patient prognosis.
Next-generation sequencing (NGS) of targeted genomic regions has become increas-
ingly common because targeted panels focus sequencing coverage on genomic regions
more likely to harbor important genomic aberrations and thereby increase diagnostic
sensitivity [3]. Oncopanels have several potential clinical applications, including identi-
fication of driver and potential driver mutations. Variants can be prioritized for their
biological significance and cross-referenced with potentially useful targeted therapies.
Some oncopanels are also used to assess micro-satellite instability [4], homologous re-
combination defect status [5], copy number alterations [6], and gene rearrangements
[7]. There is increasing evidence that a significant proportion of patients with low-
frequency alleles of these clinically actionable mutations show clinical response to tar-
geted therapies [8]. Because key therapeutic decisions are based on these results,
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including choice of molecular-targeted therapy and prediction of outcomes, it is critical
that mutation detection displays high sensitivity and low false positive (FP) rate and
that reports to physicians are highly accurate [9–11]. Importantly, both oncopanels and
downstream bioinformatic methods must be validated to be accurate, informative, and
reliable.
Certain tumors that are genetically unstable may result in a large number of cellular
proteins having somatic mutations (also known as neoantigens). More exposure of
neoantigens increases the likelihood of non-self recognition by the adaptive immune
system. If such a recognition event has occurred, but the tumor still progresses, a pos-
sible reason is the autoregulatory process of immune checkpoints which ordinarily pre-
vent autoimmunity by deactivating active T cells in the tumor microenvironment.
Therefore, if oncopanels are large enough in size, they can be used to estimate tumor
mutational burden (TMB), an emerging indicator for immune checkpoint inhibitors in
certain tumor types [12, 13].
In current practice, there are multiple Clinical Laboratory Improvement Amend-
ments (CLIA)-certified labs that have implemented oncopanels for tumor profiling. At
present, four pan-cancer panels have been approved or cleared by U.S. Food and Drug
Administration (FDA): FoundationOne CDx [14], MSK- IMPACT [10], NantHealth
Omics Core [15], and PGDx elio tissue complete [16]. In 2017, the FDA approved
Merck’s Keytruda (pembrolizumab) for any unresectable or metastatic solid tumor with
evidence of mismatch repair deficiency. Thus, this was the first approval that was
biomarker-based and tissue agnostic [17]. The FDA accelerated the approval of Bayer’s
Vitrakvi in 2018, and Roche’s Rozlytrek (entrectinib) in 2019, both of which are
biomarker-based cancer treatments [18]. However, only a minority of cancer patients
undergo high-throughput mutational profiling [19] and many physicians remain
skeptical of the rigorousness of genomic testing [20], hesitant to deplete precious tumor
material, and/or apprehensive about performing an additional tumor biopsy [21]. For
oncopanel sequencing to become a useful and widely adopted clinical test, a thorough
understanding of its sensitivity, reproducibility, and accuracy is greatly needed. To date,
no study has assessed how distinct oncopanel methodologies perform with respect to
variant allele frequency (VAF) and variant location, impacting sensitivity, FP rate, re-
producibility, and potential biomarkers such as TMB for oncopanels. Previous studies
comparing oncopanels have not used reference materials as test samples with (1)
enough VAF range and sufficient diversity of mutations to thoroughly interrogate a suf-
ficient number of clinically relevant mutations [22] and (2) sufficient material readily
available for the scientific community [23–25]. In contrast, this study used recently
characterized reference samples that contain an extensive collection of known positive
and negative variants [26] to provide a much more definitive and comprehensive un-
derstanding of key variables that impact performance of oncopanels.
The FDA-led SEquencing and Quality Control project phase 2 (SEQC2) continues
earlier consortium efforts [27–30] to advance best practices and address the technical
gaps in genomics technologies. Its Somatic Mutation Working Group has extensively
identified variant content of an individual pair of reference samples (breast cancer cell
line HCC1395 and its normal counterpart) and established best practices for genome-
wide somatic mutation calling [31, 32]. In parallel, the Oncopanel Sequencing Working
Group’s efforts, which are detailed herein, utilize a recently identified novel set of
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comprehensive variants and negatives [26] from additional reference samples to com-
pare variant calling across eight distinct oncopanels. We assessed intra-lab and cross-
lab reproducibility, sensitivity for known positives, and accuracy (i.e., FP rate) through
known negatives across a range of VAFs and in selected important genomic regions.
The relationships between analytical variables and TMB estimation were also estab-
lished to inform the selection of oncopanel and harmonization of TMB measurements
across test platforms, which are important needs [33] identified recently to advance the
successful utilization of TMB in clinical practice. This study provided a comprehensive
evaluation of eight oncopanels to inform best practice guidelines for oncopanel sequen-
cing (Table 1).
Results
Overview of study design
We employed four reference samples (Fig. 1a)—sample A (an equal mass pooled gen-
omic DNA (gDNA) sample of ten cancer cell lines from the Agilent Universal Human
Reference RNA (UHRR) material) [34], sample B (derived from a non-cancer male cell
line), sample C (equal dilution of sample A and sample B), and a spike-in sample (sam-
ple B with 5% AcroMetrix hotspot synthetic controls [35]). The majority (about two
Table 1 Summary of recommendations
Issue Recommendation
Reference material selection A reference material (or a set of reference materials) with a high density of
known variants spanning a range of low allele frequencies (e.g., from above
1 to 20%) is needed to assess the analytical performance of oncopanels
(Fig. 1a). Ideally, the reference material will encompass a diversity of simple
and complex variants in different cancer-associated genes.
Sensitivity Sensitivity was found to be high (> 96.5%) for variants previously verified to
have variant allele frequency (VAF) greater than 5% (Fig. 2a). We recommend
that a less stringent VAF threshold is used to achieve high sensitivity for
variants of VAF below 5%.
Spike-in Utilizing a sample spiked-in at a specified amount (e.g., 5%) can provide add-
itional variants at known allele frequencies for analytical validation of
oncopanels.
Variant type The sensitivity for detecting insertion and deletion variants (indels) is
typically more variable and poorer than single nucleotide variants (SNVs),
and this difference becomes more pronounced at low VAFs (Fig. 3). We
recommend that analytical validation of indels is performed independently
to SNVs.
Determining VAF threshold Reference materials can be used to establish an optimal VAF threshold that
reduces false positives (FPs) and retains sensitivity. Indels and SNVs may
require different VAF thresholds to optimize performance (Fig. 3b).
Controlling the FP rate In applications where a minimal FP rate is required, raising the allele
frequency threshold was effective at reducing FPs. The additional restriction
of analysis to the consensus targeted regions (CTR) can further reduce FP
rate.
Genomic location Genomic location can impact the rate of FPs detected, and we recommend
that analytical validation of panels is independently performed inside and
outside of the CTR (Fig. 4a).
Cross-lab reproducibility Measuring the analytical performance of a panel in multiple labs is critical to
establish reproducibility (Fig. 4c).
Estimating tumor mutational
burden (TMB)
TMB estimation should be confined to the CTR of each panel. Applying a
minimal VAF threshold was helpful to reduce FPs and improve TMB
evaluation (Fig. 5d).
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thirds) of more than 42,000 known small variants (including SNVs, small indels, and
multi-nucleotide variants (MNVs)) in the 22-Mb exon coding regions of sample A have
a VAF below 20%, making sample A uniquely suitable for assessing the analytical per-
formance of oncopanels. Sample C was included to increase the number of known vari-
ants with VAF between 1 and 2.5%. More details about the four reference samples are
included in “Methods.” A total of eight oncopanels from eight distinct well-established
panel providers were tested herein on these four samples, including Agilent Custom
Comprehensive Cancer Panel v2 (AGL), Burning Rock DX OncoScreen Plus (BRP), In-
tegrated DNA Technologies xGen Pan-Cancer Panel (IDT), iGeneTech AIOnco-seq
(IGT), Illumina TruSight Tumor 170 (ILM), QIAGEN Comprehensive cancer panel
(QGN), Roche SeqCap EZ Choice custom PHC Panel (ROC), and Thermo Fisher
Oncomine Comprehensive Assay v3 (TFS). Vendors shipped the same reagent kits to
all sites. Information about the oncopanels is included in Fig. 1b and Additional file 1:
Table S1.
Each panel was tested in at least three independent laboratories with quadruplicates
for each sample. In total, this unprecedented large-scale study encompassed 28 labora-
tories and 430 libraries (Fig. 1c). Each panel provider recruited the test laboratories and
harmonized the experimental protocols to minimize cross-lab variations in the study.
Libraries were sequenced on the same sequencing platform for each panel and the
panel provider then performed panel-specific variant calling. For more information
about sequencing and downstream bioinformatic pipelines, please see Additional file 2:
Supplementary Methods. Variant calling results were submitted in variant call format
(VCF) files, along with their targeted regions and whitelist/blacklist, to an independent
group with sole knowledge of the known content of samples A, B, C, and the spike-in
for performance evaluation (Fig. 1d). Intra-lab and cross-lab reproducibility were
Fig. 1 Comprehensive study design for assessing analytical performance of multiple pan-cancer targeted
sequencing technologies. a Four samples were tested on 8 pan-cancer panels with at least 3 different test
laboratories for each panel. b Basic information of 8 pan-cancer panels is listed in the embedded table (see
Additional file 1: Table S1 for detailed information). *All participating panels are for research use only.
†QGN’s UMI-aware variant caller is able to call variants with VAF as low as 0.5%. c Each sample had 4 library
replicates at each test laboratory. After sequencing, panel-specific variant calling was performed by each
panel vendor. d Variant calling results were submitted for performance analysis including sensitivity, false
positive call rate, and reproducibility
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computed between library replicates as a measure of variant calling consistency. Sensi-
tivity and FP rate were then estimated by utilizing the large sets of known positive (KP)
and known negative (KN) loci from our companion work [26]. More than 42,000 KPs
and 10 million KNs in sample A were characterized in the 22-Mb high-confidence exon
coding regions through extensive sequencing of sample A and the individual cell line
DNA samples that made up sample A. KN loci had the mismatch error rate below
0.25%. The distribution of KPs by VAF is shown in Fig. 1a.
Sensitive detection of SNVs in the focused regions by all panels
We evaluated the performance of detecting SNVs in the consensus targeted regions
(CTR, see “Methods” for details) [26]. Given there is a general consensus that higher
VAF variants are “easier” to detect, we focused our analysis on metrics that character-
ized performance relative to VAF, especially in the lower [1–10%] VAF range (Fig. 2).
The number of KPs and observed sensitivity are listed side by side for each VAF range
across three reference samples (A, C, and spike-in) and all panels (Fig. 2a). Sample C
was not tested by TFS. Overall, sensitivity across all VAF ranges in all panels was high
with narrow confidence intervals (Additional file 1: Table S2). It ranged from 87.1 to
98.3% for the lowest VAF range (1–2.5%) tested by AGL, BRP, IGT, and QGN (Fig. 2a).
Sensitivity was greater than 96.8% for the 2.5–5% range and greater than 98.4% for the
5–20% range. The unusual sensitivity for ILM in sample C for the 10–20% range was
due to a single false negative in all library replicates. Other exceptions were ILM, ROC,
and TFS for the 2.5–5% range, as their variant calling pipelines had a VAF reporting
threshold very close to 2.5%. So their sensitivity was reduced due to a boundary VAF
threshold effect (see below for the effect of VAF cutoff on sensitivity). Accordingly,
Fig. 2 Reproducibility and sensitivity across VAF ranges for SNVs in the consensus targeted regions. a Table
listed the number of known variants in each VAF range (left number), sensitivity (right number) for all 8
panels across all samples tested. For the panels with a built-in VAF threshold, “N/A” is listed if the VAF low
bound is much lower than the panel provider’s chosen VAF threshold. The VAF threshold is 2.6% for ILM,
2.0% for IDT, 2.5% for ROC, and 2.5% for TFS, respectively. b Average false positive SNV calls per million
across various VAF cutoffs. Jittering was applied to avoid overlapping. c Cross-lab and intra-lab
reproducibility (in Phred scale) for variant calls with VAF between 2.5 and 20%
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these threshold-dependent panels and IDT were not assessed for the lowest VAF range
(since IDT’s pipeline utilizes a VAF reporting threshold of 2.0%). All false negatives in
sample A or C were manually checked and can be explained by a combination of low
VAF and the panel’s VAF threshold except the above mentioned single case for ILM in
sample C. We initially anticipated similar sensitivity for the spike-in sample in the VAF
range of 2.5–10%, as the variants were designed to be 5% VAF. However, this was not
observed, likely due to interference of the nearby spike-in variants with amplicon
primers, DNA capture, or variant calling. To derive sensitivity estimates, custom filter-
ing of the spike-in’s variants was carried out by the panel providers to exclude variants
under primer interference for QGN and TFS or variants in dense clusters for IDT (see
Additional file 2: Supplementary Methods for details). Likewise, several dense variant
clusters led to unexpectedly low reported sensitivity for ROC (88.0%).
All panels had FP rates lower than 10.5 per Mb in the CTR with each panel’s default
VAF threshold, and the FP rates dropped as the VAF cutoff increased (Fig. 2b). The FP
rate was noticeably different between panels for a VAF cutoff at 1%, but became in-
creasingly similar as the VAF cutoff became more stringent. As a result, all panels had
similar FP rates of approximately 1 FP per Mb or less for VAF greater than 5%. And all
panels reported no FP calls for VAF greater than 10%. We also assessed both intra- and
cross-lab reproducibility for variant calls in the CTR with VAF between 2.5 and 20%
and observed that they were similar for each panel sample combination (Fig. 2c, Add-
itional file 3: Fig. S1A), with cross-lab reproducibility being slightly worse than intra-lab
reproducibility in a few instances. Results for sample A and sample C were similar for
VAF above 5% but showed some noticeable differences in the VAF range 2.5–5%. The
differences may be driven by VAF reporting boundary effects, as sample C has more
variants in the lower VAF ranges (thus, near the VAF reporting thresholds for several
panels) (Additional file 3: Fig. S1B).
Impact of variant type, VAF cutoff, and genomic region on sensitivity
We explored the impact of variant type on sensitivity for each panel by aggregating all
sample A and C libraries (Fig. 3a). Non-SNV variant calling (small indels and multi-
nucleotide variants (MNVs)) had more variable sensitivity than SNV variant calling for
AGL, ILM, and ROC panels, as the number of known non-SNV small variants per
panel in samples A and C is typically small by absolute numbers (green numbers in
Fig. 3a, Additional file 3: Fig. S2). Thus the confidence interval was usually wider for
non-SNV small variants (Additional file 1: Table S3). We characterized the impact of
VAF on sensitivity comparing SNVs against non-SNV variants (Additional file 3: Fig.
S2). For sample A, the difference between SNVs and non-SNV variants was most pro-
nounced in the lowest VAF range. For both SNVs and non-SNV variants, sensitivity
was generally observed to improve with known variants of higher expected VAFs.
We also applied a range of artificial VAF cutoffs in addition to each panel’s normal
reporting thresholds from stringent (2.5%) to less stringent (1.5%) to better understand
the impact of a VAF reporting threshold on sensitivity in detecting known positives in
the VAF range 2.5–5% (Fig. 3b, see Additional file 1: Table S4 for confidence intervals).
As the cutoff filter was more relaxed, and the boundary effects decreased, sensitivity
rose expectedly across most panels and all reference samples. This increased sensitivity
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was more prominent in samples A and C, which may be explained by the fixed and
higher VAF (5%) for variants in the spike-in sample. The boundary effects became neg-
ligible for the higher VAF ranges, i.e., 5–10% and 10–20%, in samples A and C (Add-
itional file 1: Table S5).
Sensitivity within the CTR and outside of the CTR, but inside the High Confidence
Coding Region (HC_CR, see “Methods” for details), was compared (Fig. 3c). For sam-
ples A and C, most panels performed consistently within and outside of the CTR (but
within HC_CR). TFS, ILM (for sample C), and ROC had higher observed sensitivity
outside of the CTR, but also had relatively few KPs in this region (Fig. 3c top bar
graph). Thus narrower confidence intervals for sensitivity were achieved within the
CTR (Additional file 1: Table S6).
False positive rates were significantly higher beyond the focused regions
We employed three different methods to estimate the FP rate. Method 1 relies on the
KNs (“via_KN”) in samples A and C (Additional file 3: Fig. S3A). Our list of KNs is ex-
tensive (> 10M) but only available within the CTR (which is the majority of the coding
region) and comprises about 30% of all coding regions. Using Method 1, a FP is a vari-
ant call on a KN position. A stringent consensus across multiple sequencing experi-
ments was employed to determine the partial list of negatives within the CTR [26].
Method 1 may tend to underestimate the overall FP rate across all positions of the
CTR. Method 2 marked any call in the normal sample B with VAF between 1 and 10%
as a false positive (“B_low,” Additional file 3: Fig. S3B) due to strong evidence of this
sample having normal diploid cell characteristics [26]. Method 3 leveraged sample mix-
ture to differentiate FPs. Any variant call in sample C was deemed an FP if it was not
called in any of four sample B libraries with VAF above 10% or any of four sample A li-
braries at the same test laboratory (“C_only,” Additional file 3: Fig. S3C). Method 2
Fig. 3 Impact of VAF cutoff, variant type, and genomic region on sensitivity (in Phred scale). a Violin
distribution plots of estimated sensitivity for each panel in all sample A and C libraries for known SNVs (in
blue on the left side) and other variants (small indels or MNVs, in green on the adjacent right side) with
VAF between 2.5 and 20%. Total numbers of small indels and MNVs are listed under the corresponding
violin plot. b Artificial VAF filters reduce sensitivity for known positives with VAF between 2.5 and 5% due to
the variable VAF measurements. c High concordance of sensitivity in and outside of CTR (more specifically,
in HC_CR beyond CTR) for known positives with VAF between 2.5 and 20%. Jittering was applied to one
dot at the top right corner to avoid overlapping
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might overestimate the FP rate by failing to exclude rare mosaic variants caused by cell
line drift. Method 3 could underestimate the FP rate by failing to recognize those FP
calls due to systematic errors as they would be called in all three samples. These three
methods were compared and found to produce largely similar estimates within the
CTR (Additional file 3: Fig. S3D), with the “B_low” method in one specific VAF range
of IGT and ILM being the only exception. As expected, almost all FP calls within the
CTR were irreproducible across library replicates for any panel, sample, and FP method
(Additional file 3: Fig. S4). Those few exceptions were then confirmed through manual
curation as systematic errors (see the legend for Additional file 3: Fig. S4).
Using the last two methods (“B_low” and “C_only”), we compared the FP rate within
and outside of the CTR (Fig. 4a). By either method, across VAF ranges and across
panels, we observed that the FP rate was lower in the CTR than outside. Breaking each
panel into three sub-regions (inside the CTR, outside the CTR but in HC_CR, or the
rest with the subregion sizes listed in Additional file 3: Fig. S3E), the FP rate was
the lowest in the CTR and the highest outside of the HC_CR when using either the B_
low or C_only method (Additional file 3: Fig. S3F-G). FP rates inside the CTR across
different VAF cutoffs are listed in Fig. 4b. For all panels, the FP rate decreased as the
VAF increased.
Finally, to better understand the impact of genomic regions on cross-lab reproduci-
bility, we assessed cross-lab reproducibility within and outside of the CTR with VAF
between 2.5 and 20% (Fig. 4c). Across most panels and in both samples A and C, cross-
lab reproducibility was marginally lower outside of the CTR. Taken together, these re-
sults suggest that variant location may drive high cross-lab reproducibility seen in
Fig. 4 Impact of CTR region on FP rate and reproducibility. a FP rate in and outside of the CTR using two
different methods (B_low and C_only) at three different VAF cutoffs, 1%, 2.5%, and 5%. C_only was not
applied to TFS as sample C was not tested on TFS. FP rates are plotted in squared root scale. b Estimated
FP rate within the CTR averaged over three methods at different VAF cutoffs. c Cross-lab reproducibility (in
Phred scale) in samples A and C within and outside of the CTR
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Fig. 2c. Since sensitivity did not drop noticeably outside the CTR (Fig. 3c), the observed
drops in reproducibility (Fig. 4c) may be driven by more FPs outside of the CTR
(Fig. 4a).
Enabling oncopanels of sufficient size to estimate TMB
Commonly measured by whole-exome sequencing (WES), TMB ranges over several or-
ders of magnitude and varies by tumor type. Suitable TMB biomarker thresholds can
also vary by tumor type, implying different degrees of accuracy may be required
for different indications. The elevated FP rate outside of the CTR will have a
strong detrimental effect on the accuracy of variant calls and subsequently TMB
estimates. This leads to a reasonable requirement that TMB estimation should be
confined to the CTR portion of each panel. The high density of variants in these
reference samples was purposely designed to enable an accurate evaluation of sen-
sitivity and limit of detection. To investigate a more “real-world” scenario where
using an oncopanel to estimate exome-level TMB might be relevant, we randomly
selected known variants comprised of a prevalence more consistent with actual tu-
mors for a variety of indications (e.g., between 5 and 50 per Mb). We then com-
puted the average technical run-to-run variance of panel-focused TMB estimates
and plotted the technical coefficient of variation (CV) at two different VAF cutoffs:
Fig. 5 Coefficient of variation (CV) of TMB. a Technical run-to-run variance of TMB with VAF cutoff above
2.5% was estimated for six panels at different TMB levels. A power-law curve (dashed line) is fitted for each
panel. b Technical run-to-run variance of TMB with VAF cutoff above 5%. c The intrinsic CV is plotted with
the equation (embedded, see “Methods” for detail) for each panel based on their panel size. The curve
(dashed) for size of 1 Mb is also plotted as a reference. d The overall CV is plotted combining technical and
intrinsic CV. The solid fitting power-law curve is for TMB (VAF > 2.5%), and the dashed curve is for
TMB (VAF > 5%)
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2.5% (Fig. 5a) and 5% (Fig. 5b, see “Methods” for details). All six panels with tar-
geted regions in the CTR greater than 250 kb were included in the analysis.
Clearly, the technical CV decreased at higher panel TMB values. There was no ob-
served effect related to the panel size. All panels achieved a CV lower than 25%
when panel-focused TMB was 25 or higher.
To assess the magnitude of additional variance introduced by the genomic coverage
of oncopanels, we utilized The Cancer Genome Atlas (TCGA) WES mutation data [36]
to compute TMB estimates using each panel’s CTR portion. We then used the mean
squared deviation (MSD) to measure the TMB estimation difference between whole-
exome and the panel-specific CTR portion. MSD has two components: mean bias and
variance. We characterized an intrinsic CV measure specific to each panel, related to
this variance component. Further linear regression analysis led to an approximate
equation estimating the intrinsic CV by TMB and the panel size (Additional file 3: Fig.
S5, see “Methods” for details). The intrinsic CV is plotted in Fig. 5c. In agreement with
technical CV, intrinsic CV decreases at higher TMB values. For example, a 1-Mb onco-
panel is estimated to have an intrinsic CV of 25% at a TMB value of 21. By incorporat-
ing both technical variance and intrinsic variance, an overall CV for TMB was
computed and plotted in Fig. 5d when using VAF cutoffs of 2.5% and 5% for each
panel. Overall CV was close to intrinsic CV for each panel at corresponding TMB
values. This indicates that all panels were able to achieve a lower technical variance
than the intrinsic variance associated with estimating exome-level TMB from a smaller
focused panel. Nevertheless, lower technical run-to-run variance is possible for all
panels using a higher VAF cutoff as illustrated in Fig. 5d. This improvement was more
apparent for AGL and QGN panels at lower TMB, and consistently large for IDT
across a wide TMB range. Although many of the panels, e.g., QGN, were not designed
for TMB estimation, they may be used to do so under certain circumstances. However,
if the goal is to maintain an overall CV lower than 25% in the clinically important TMB
range between 15 and 30, AGL combined with an VAF cutoff at 5% would be the only
panel from these eight suitable for TMB estimation.
Discussion
This oncopanel study was comprehensive in several areas: (1) the use of rigorous per-
formance metrics both within and outside of easier/difficult genomic regions, (2)
utilization of various oncopanel vendors with different panel sizes, (3) broad multi-
laboratory participation, (4) analysis of a wide dynamic range of VAFs, and (5) use of
test samples comprising advanced reference material with dense, known variant content
from a stable source. We assessed reproducibility, sensitivity, and the FP rate of eight
pan-cancer oncopanels across laboratories. We examined the impact on these metrics
by VAF ranges, variant types, and genomic regions. These panels ranged in size from as
small as 149 up to 7625 kb, and DNA input ranged from 20 to 100 ng. Enrichment of
targets by both hybridization-based capture and PCR amplification were represented.
The panel vendors represented major providers of currently marketed targeted sequen-
cing technologies.
We cannot be completely certain that all of our results would generalize to a new ad-
mixture reference sample similarly constructed or real-world clinical formalin-fixed
paraffin-embedded (FFPE) samples. Our primary reference sample (sample A) does not
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reflect all cancer indications, nor does it reflect all subtypes for any given cancer [26].
However, this approach provided noticeably better estimates than previous efforts [24].
For example, the large number of variants present in diverse sequence contexts in sam-
ples A and C enabled an accurate assessment of sensitivity and reproducibility for de-
tecting SNVs. We observed that these panels detected known small indel or MNV
positives with similar sensitivity and reproducibility as SNVs (Fig. 3a, Additional file 3:
Fig. S2). However, with the limited amount of small indel/MNV positives identified as
a proportion of all identified variants in the reference sample (1.2%), it is likely given
prior research in the field that these small indel/MNV positives identified in the refer-
ence sample are in group that is easier to detect, in general. Therefore, we cannot sug-
gest that these panels find small indels/MNVs with the same proficiency as SNVs
throughout their target regions until we have identified a larger and more representa-
tive set of indels/MNVs from which to compare. While SNVs predominate clinically
relevant oncology mutations, non-SNVs can also be key drivers [37], and panels should
be further characterized for analysis of non-SNVs as these variants are typically more
challenging to detect than SNVs. Additional reference material with more complex var-
iants is required to address this outstanding question.
We chose to use the output of vendor-implemented bioinformatics pipelines for their
respective proprietary panels. Other SEQC2 work has clearly demonstrated that choices
of bioinformatics pipelines will influence the variant calling results in WES and whole-
genome sequencing (WGS) [31]. Our raw data are made public to enable further evalu-
ation of various bioinformatics pipelines by the community. This study did not
characterize the effect of read coverage, which can be critical for low VAF variants.
Low read coverage can reduce sensitivity and sometimes inflate the FP rate [38]. In
addition, this study did not explore the impact of sample quality on variant calling. In
the clinical setting, it can take considerable time before samples are processed, and
samples are often subject to formalin fixation. A separate team from the Oncopanel Se-
quencing Working Group revealed the impact of formalin fixiation time and within
block position on the performance of oncopanel sequencing [39]. Taken together, the
experience gained from this study suggests that future analysis should focus on asses-
sing the impact of bioinformatics pipelines, including variant callers, on sensitivity and
FP rates.
The FP rate impacts TMB and overall confidence in the panel. To the best of our
knowledge, this is the first study with a comprehensive analysis of the FP rate for onco-
panels. Importantly, our results revealed that increasing the VAF reporting threshold
reduced the FP rate across all VAF values within the CTR, but this effect was far less
dramatic outside of the CTR. Therefore, one straightforward way to control the FP rate,
at least within the CTR, is to adjust the VAF reporting threshold, which for different
panel implementation modalities, may be optimally and more simply determined by
assaying our reference samples and additional negative (normal) reference material
using multiple technical replicates and cross-lab testing. On the contrary, if the goal is
to have sensitive detection of clinically actionable mutations, where the FP rate over a
region is not so relevant, lower variant-specific VAF threshold can be used without
compromising accuracy through a novel synthetic spike-in control that directly mea-
sures the variant-specific and experiment-specific background errors. The control is
presented in an accompanying SEQC2 manuscript [40].
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To understand the impact of genomic region on sensitivity, reproducibility, and FP
rates, we assessed all variants compared to those only within the CTR. Sensitivity was
consistent for each panel between the CTR and HC_CR (Fig. 3c). However, because
known variants were only available within HC_CR, we were not able to assess sensitiv-
ity for the regions outside of HC_CR. We hypothesize that sensitivity would be the
same outside of HC_CR or slightly lowered. As for the FP rate, we observed multiple
fold increases for all panels outside of the CTR when studying the impact of genomic
region (Fig. 4a). Reproducibility was lower outside of the CTR (Fig. 4c). A plausible in-
ference would be that the much higher FP rate outside of the CTR led to lower repro-
ducibility in that region. “Real-world” clinical samples likely harbor much fewer low
VAF variants (i.e., VAF < 20%) than sample A or C that was used here. With fewer vari-
ants, the effect of FP rate on reproducibility will be even more pronounced, i.e., the
change in reproducibility will be greater between the CTR and outside of the CTR. In the
extreme case of samples without any low VAF variants, e.g., a pure sample from a healthy
infant, reproducibility will be completely dependent on the FP calls with no relationship
to sensitivity. When reproducibility would play an important role in the specific applica-
tion of oncopanel sequencing, for example, profiling multiple samples to study intratumor
genetic heterogeneity, one may consider restricting the analysis to the CTR. Although
most pathogenic mutations are within the CTR [26], restricting the analysis of clinical
samples to the CTR may lead to the exclusion of certain mutations of interest. Currently,
the CTR has excluded difficult regions and places likely to cause systematic sequencing
errors. Extending the CTR will be a good direction for future work.
We noted that cross-lab reproducibility is similar to, but generally lower than intra-
lab reproducibility (Additional file 3: Fig. S1A). The VAF range has a greater impact
than the lab on reproducibility; however, given the increased variability across labs, we
encourage cross-lab testing of oncopanels. If this is not possible, an alternative is more
extensive testing within the same lab with different operators over an extended period.
Furthermore, routine proficiency testing will help safeguard the performance, even
within the same lab.
When screening clinically actionable mutations, FP variants are typically filtered by
various processes, including variant prioritization (where only selected variants are con-
sidered for determining targeted therapy), and therefore have a small impact in final
clinical decisions [10, 25]. In contrast, FP calls could easily confound TMB calculations
and create a noninformative biomarker. Based on the findings of this large-scale cross-
panel study, we propose different filtering and threshold-related methods for different
modalities: variants for prioritization and targeted therapy selection may employ lower
VAF reporting thresholds to achieve maximal sensitivity, while variants used in TMB
calculations for immunotherapy purposes should consider higher VAF reporting
thresholds or use VAF cutoffs commensurate with a low FP rate. Within this study, we
have evaluated the impact of analytical variables on the detection of mutations and
TMB estimation without reference to specific cancer subtypes. While the described re-
lationships between analytical variables and TMB estimation are likely to remain con-
stant regardless of cancer subtypes, the cancer type may inform the selection of
oncopanel and VAF threshold to optimize diagnostic yields. For example, a greater mu-
tation density, which is typical in lung cancers and melanomas, will enable a more
confident estimation of TMB with lower overall CVs (as shown in Fig. 5d for high
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TMB values). Therefore, a moderately sized oncopanel with a higher VAF threshold
may be sufficient. Alternatively, lower VAFs, which confound confident diagnosis, are
typical in cancers with lower sample purity or greater intratumor heterogeneity, such as
pancreatic cancers. In these cancers, a larger oncopanel with a lower VAF threshold
may be required to confidently estimate TMB.
In summary, all eight panels achieved high sensitivity (ranging from 84.2 to 100%) for
variants of low VAF between 1 and 5% (Fig. 2a). Applying an increasingly strict VAF
cutoff reduces the FP rate, but also reduces sensitivity (Fig. 3b). VAF reporting thresh-
olds create boundary effects due to stochastic sampling, where a variant may have an
observed VAF just above the threshold in one replicate and but below in another, caus-
ing a decrease in sensitivity and reproducibility. When comparing performance metrics
in different genomic regions, sensitivity remains consistent; however, the FP rate is
higher and consequentially reproducibility is lower outside of the CTR. These oncopa-
nels demonstrated low relative technical variability in estimating TMB; however, due to
the greater variability in sampling a much smaller region of the exome (Fig. 5), our re-
sults suggest that, at a minimum, oncopanels will require 1Mb in the CTR region to
properly estimate TMB at levels commonly used for decision thresholds and may re-
quire even larger panels if TMB thresholds are needed below 10–15 mutations per
megabase. Results are generally consistent with previous in silico studies [41–43]. This
comprehensive study provides actionable guidelines for oncopanel sequencing and clear
evidence that supports a simplified approach to assess the analytical performance of
oncopanels. It will facilitate the rapid implementation, validation, and quality control of
oncopanels in clinical use.
Methods
Testing samples
Realizing that there is no adequate reference genomic material to enable a transparent
cross-lab study of oncopanels, the Oncopanel Sequencing Working Group developed
and validated a genomic sample suitable for benchmarking oncopanel’s performance in
detecting small variants of low allele frequency (AF). The design, validation process,
and the results are reported in a companion paper [26]. This sample, termed “sample
A,” is composed of an equal mass pooling of 10 gDNA samples prepared from Agilent’s
Universal Human Reference RNA (UHRR) [34] cancer cell lines. Over 42K small vari-
ants are called with high confidence in the defined CTR of over 22 million bases.
Briefly, CTR is the overlap of targeted regions of four whole-exome sequencing panels,
UCSC coding genes, Ensemble exons, and NIST high-confidence genomic regions,
followed by a removal of low complexity regions [26]. The majority of these small vari-
ants have a VAF below 20%, making sample A uniquely suitable for assessing the ana-
lytical performance of oncology panels. More specifically, about 7% of them are in
variant allele frequency (VAF) range (1%, 2.5%), 18% in (2.5%, 5%), 25% in (5%, 10%),
and 18% in (10%, 20%). Sample B is a gDNA sample from a normal male cell line (Agi-
lent Human Reference DNA, Male, Agilent part #: 5190-8848). Sample C is a 1:1 mix
of sample A and sample B. Sample C was included to increase the number of known
variants with VAF between 1 and 2.5%. The spike-in sample is sample B with 5% Acro-
Metrix29 Spike hotspot synthetic controls (Thermo Fisher Scientific, Fremont, CA).
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Samples A, B, and C were prepared by Agilent and provided without charge to SEQC2
for study. The spike-in sample was prepared at Thermo Fisher Scientific (Fremont, CA)
after receiving sample B from Agilent under their material transfer agreement. All four
samples were stored in low-EDTA TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0) at
20 ng/μl concentration.
Participating panels, test sites, and study protocol
Study participation of oncopanel vendors was actively sought out through all available
venues. A study plan was discussed in detail with each interested contact, emphasizing
the cross-lab study design, transparency, and the requirement for eventual data release
to the public domain. Eight panel providers agreed to participate. Each panel provider
then recruited independent test sites (i.e., laboratories) that were proficient with its
panel and oncology sequencing procedure. Test samples were distributed to test sites
after executing Agilent material transfer agreement and SEQC2 confidentiality agree-
ment. A sample processing and sequence data reporting standard operating procedure
(SOP) was also distributed to all test sites. It includes test sample description, sample
receiving and preparation, a list of test sites, naming convention, testing procedure,
and instructions on library preparation quality data collection. There were at least
three independent test sites for each participating panel. Panel providers and their
supporting partners distributed panels and reagents to the corresponding test sites.
Each site followed the SOP and a panel-specific experimental protocol (see Add-
itional file 2: Supplementary Methods for details) to make 4 replicate libraries for
each sample. Sequencing was done on the same sequencing platform for each
panel. Each panel provider determined the depth of coverage per library and sam-
ple C libraries were sequenced twice as deep as other samples. Panel providers
were encouraged to conduct pilot sequencing experiments with test samples at
their internal lab or test sites. Pilot data was not required for submission to
SEQC2.
Reproducibility by VAF ranges per panel
Given the variability in VAF measurements and its influence on reproducibility, a non-
symmetric reproducibility measure was devised. For comparing library “Libx” to an-
other replicate “Liby” of the same sample, reproducibility is defined as the portion of
Libx’s variant calls that are also detected in Liby. It can be computed by dividing the
number of variants called in both Libx and Liby by the number of variant calls in Libx.
Similarly, a reproducibility value can be computed for comparing Liby to Libx. These
two reproducibility values are not symmetric and thus may be different. For comparing
Libx to Liby, VAF ranges are applied unsymmetrically to compute reproducibility
through stratifying variant calls of Libx into VAF ranges with no restriction imposed to
variant calls of Liby. When both library replicates are from a same test lab, it is counted
as one intra-lab reproducibility measurement. When they are from different test labs, it
is counted as one cross-lab reproducibility measurement. As there are multiple library
replicates from multiple labs, many reproducibility measurements can be computed for
each sample. The average intra-lab reproducibility indicates what percentage of variants
called by one library in one lab within a specific VAF range will be detected by another
Gong et al. Genome Biology          (2021) 22:109 Page 15 of 23
library replicate in the same lab without any restriction to their VAF values. The aver-
age cross-lab reproducibility may be interpreted similarly.
Sensitivity estimation by VAF ranges
Sensitivity is defined as the portion of known variants detected by each panel sequen-
cing experiment among all the KPs targeted by the panel. As the list of KPs was not all
inclusive, sensitivity was provided as an estimate. Fortunately, the number of known
variants was usually high enough to provide an accurate estimate. For each sensi-
tivity estimate, a 95% confidence interval was calculated by bootstrap resampling
with the assumption that library replicates are not independent. Sensitivity esti-
mates can be further stratified by the VAF of known variants. Four VAF ranges
were adopted in this study, 1–2.5%, 2.5–5%, 5–10%, and 10–20%. For the spike-in
sample, there was a single range around 5% as all AcroMetrix variants were
spiked-in at a VAF of 5%.
FP rate estimation approaches
Three approaches were adopted to estimate false positive (FP) rate. In the CTR, a list
of known negative (KN) positions was provided for sample A. This list covers over 50%
of the CTR, enough for an accurate estimation of FP rate. By removing the positions
overlapping with any known variants in sample B, a separate list of KN positions was
generated for sample C. Any variant calls overlapping with the negative positions are
flagged as FPs. FP rate is estimated as the ratio of FP calls out of every million KN posi-
tions. This is the first approach (coded as “viaKN”), applicable to sample A and sample
C, but limited to the CTR.
By the second approach (coded as “B_low”), any calls in the normal sample B with
VAF between 1 and 10% are marked as false positives (FPs). A pure diploid normal
sample has variants at either 50% (heterozygous) or 100% (homozygous). Stochastic
sampling and the influence of copy number variation lead to VAF deviation from those
two values. As no extremely high copy number variation was observed in sample B, it
is reasonable to assume that variant calls in sample B with VAF below 10% are FPs.
Variant calls with VAF greater than 10% in any of other three sample B libraries at the
same test sites will be excluded. The third approach (coded as “C_only”) leveraged sam-
ple mixture to differentiate FPs. Any variant in sample C must come from either sam-
ple A or sample B. If a variant is called in one sample C library, but not in any of four
sample B libraries with VAF above 10% or any of four sample A libraries at the same
test laboratory, it is an FP. This approach is more burdensome as all three samples and
multiple libraries must be considered, but it does not rely on the assumption of sample
B’s variant VAF range or the KNs in sample A. Furthermore, it cannot detect FPs due
to any panel bias. Unlike “viaKN,” both “B_low” and “C_only” can be applied to esti-
mate FP rate in the regions beyond the CTR.
Description of three sub-regions for each panel
The CTR was defined as the overlapping regions of four whole-exome sequencing
panels that were used in the companion work21 to characterize known variants in sam-
ple A, NIST high-confidence regions, and exome coding regions. The CTR was then
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refined by removing the low complexity regions. The CTR is completely within high-
confidence exome coding regions (HC_CR) that is defined as the overlapping regions
of NIST high-confidence regions and exome coding regions. By intersecting the CTR
and HC_CR with the targeting region of each panel, three sub-regions for each panel
can be defined for performance comparison: within the CTR, within the HC_CR but
outside of the CTR, and the rest.
Evaluation of technical run-to-run variability in panel TMB estimates via simulation
The simulation aimed to reduce the variant density and reduce low VAF variants to
better mimic a “real-world” clinical sample. While the high variant density and high
percentage of variants with VAF below 5% in the test samples provided an advantage in
estimating detection sensitivity with narrow confidence intervals, they presented obsta-
cles here for the evaluation of TMB technical variability. The high variant density
(equivalent to a TMB value about 1000) in the test samples will overshadow the effect
of the FP calls and thus greatly underestimate TMB technical variability. The high
percentage (over 75% in sample C) of variants with VAF below 5% may lead to an over-
estimate of TMB technical variability due to the variability in detecting these low VAF
variants. The simulation was applied to the CTR. The resultant median VAF for low-
frequency (< 20%) KPs would be between 5 and 10%. Sample C was chosen for the
simulation analysis as there are fewer uncharacterized true variants in sample C with
VAF greater than 2.5% in comparison to sample A. All the known variants in sample B
were excluded first from our KP list and from all the variant calling results (VCF files
of library replicates) of each panel. The KPs with VAF < 5% or VAF > 40% in sample A
were also removed. In theory, no KP with VAF < 2.5% or VAF > 20% in sample C was
left. To mimic multiple samples with the constant TMB at a similar level with a clinical
sample, we kept a fixed portion of KPs that resulted in the same number of KPs across
the CTR for panel testing in the simulated samples. Specifically, based on their VAF in
sample A, k% (k = 0, 1, 2, 5, 10, 20) of KPs were retained for VAF between 10 to 40%
and 0.5 × k% of KPs were kept for VAF between 5 and 10%. Given each value, (100 −
k)% of KPs were randomly excluded from CTR to generate a base-report-region for all
the pan-cancer panels. Therefore, the variants not excluded from a VCF file were
counted as the reported calls by the library of a pan-cancer panel in a simulation run.
It is worth pointing out that the reported variants include FP calls and possibly unchar-
acterized true variants in additional to the retained KPs. Finally, 5000 rounds of simula-
tion were performed for each based-report-region with a k value greater than 0.
For each one of 5000 base-report-region with a k value (k > 0), the reported variants
were then counted for these above a chosen VAF threshold for each library replicate.
The variance and mean across all technical replicates for each panel were calculated.
Then, we computed the overall average of variance and mean over the 5000 runs of
simulation. Finally, the CV for TMB were calculated as:
CV ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Ovarall Average of Variance
p
Ovarall Average of Mean Count
The mean TMB for each chosen k value was calculated as the overall average count
of variants divided by the report region sizes of six panels. This CV is adopted to
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measure the technical run-to-run variability and examine its dependence on TMB and
VAF cutoff.
Model the deviation in TMB rate from WES by pan-cancer panels via TCGA dataset
Mutation Annotation Format (MAF) files of 10,295 cancer genomes across 33 cancer
types were collected from The Cancer Genome Atlas (TCGA) project involving 2.9
million somatic mutations (MC3 Public MAF) for TMB measurement. The shared por-
tion of TCGA coding sequence (CDS) region and the CTR with a size of 22,089,460
bases (55% of TCGA CDS) was used to calculate the TMB rate of each individual can-
cer sample. The TCGA-measured TMB rate was calculated as the number of mutations
per million bases within the shared region and used as the baseline in this analysis.
Then, given the TCGA somatic mutations as ground truth, the panel-measured TMB
rate of each cancer sample was calculated by the number of mutations within the panel
divided by the panel’s region overlapping with the CTR and TCGA CDS in million base
pairs. Two panels, ROC and TFS, were excluded from this analysis because of their
small sizes.
For each pan-cancer panel, the mean squared deviation (MSD) was utilized to evalu-





i¼1 TCGA:TMBi−P j i;TMBi;Cov j
  2
N
where j represents each panel and i is an individual cancer sample. The function Pj cal-
culates the TMB of sample i within the covered region (Covj) by panel j. N represents
the number of samples in the group for the calculation of MSD. One outlier cancer
genome TCGA-13-0889-01A-01W-0420-08 (with TCGA TMB rate of 33) was excluded
from the calculation of MSD due to the abnormally huge difference between the TMB
rates measured by TCGA WES and panels.
For a group of samples with TMB rates close to each other and thus close to their
mean value, a modified MSD (MSD´) is defined by substituting the TMB mean for the
individual TCGA TMB in the equation above. Approximately, MSD equals to MSD´
subtracting the variance of TCGA TMB in the sample group. Mathematically, MSD´
equals to the sum of the variance of TMB by the panel and the squared difference in
the mean TMB values between TCGA and the panel. Thus, MSD is broken down into
two components of mean bias and variance (see Additional file 2: Supplementary
Methods for details). The mean bias component is equal to the squared difference in
the mean TMB values between TCGA and the panel. The variance component is equal
to the variance of TMB by the panel reduced by the variance of TCGA TMB. This ad-
justed variance component is of particularly interest.
To better understand this adjusted panel TMB variance, we selected the TCGA
samples (about 2400 samples) with TMB rates from 5 to 40 and sorted them by
TMB. We then grouped each 100 samples and calculated the panel TMB mean
value and the adjusted panel TMB variance. Multiplying it by the squared panel
size in million bases, we converted the adjusted panel TMB variance to the muta-
tion count level, which was then plotted against the product of the panel TMB
mean and the panel size. A linear regression model was fitted over these two
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variables from all the six panels that cover at least 250 kb in the CTR (Additional
file 3: Fig. S5). A very high R2 value (0.957) was observed along with a tight 95%
confidence interval (1.28–1.34) for the slope of the regression line. This revealed
a strong linear relationship between the adjust panel TMB variance and the panel
TMB mean in mutation count. Finally, an intrinsic CV for each panel could be
calculated as 1.15 divided by the square root of panel TMB mean in mutation
count.
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